N
Nagahiro Saijo
Researcher at AstraZeneca
Publications - 386
Citations - 31129
Nagahiro Saijo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 65, co-authored 386 publications receiving 28187 citations. Previous affiliations of Nagahiro Saijo include Harvard University.
Papers
More filters
Journal ArticleDOI
508 POSTER Association of genetic polymorphisms with survival in Japanese pancreatic cancer patients treated with gemcitabine
Hikaru Ueno,Takuji Okusaka,Nagahiro Saijo,Junji Furuse,Yasunori Sato,Teruhiko Yoshida,E. Sugiyama,Sinil Kim,N. Kaniwa,Jun-ichi Sawada +9 more
Journal ArticleDOI
O-278 Randomized phase II study of cisplatin (P), irinotecan (I), and etoposide (E) combinations administered weekly or every four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI
Nagahiro Saijo,Ikuo Sekine,Tomohide Tamura,Yutaka Nishiwaki,Kazumasa Noda,Shinzo Kudo,Masahiro Fukuoka,Kiyoshi Mori,S. Negoro,Akira Yokoyama,Kaoru Matsui,Yoshinobu Osaki,Takashi Nakano +12 more
Journal ArticleDOI
Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L.
Koji Takeda,Tetsuya Abe,Yuichiro Ohe,Shinzoh Kudoh,Yukito Ichinose,Hiroaki Okamoto,Nobuyuki Yamamoto,Hiroshige Yoshioka,Koichi Minato,Toshiyuki Sawa,Yasuo Iwamoto,Hideo Saka,Junki Mizusawa,Tomonori Mizutani,Shinichiro Nakamura,Masahiko Ando,Akira Yokoyama,Kazuhiko Nakagawa,Nagahiro Saijo,Tomohide Tamura +19 more
TL;DR: This final survival analysis aimed to confirm the result of the first interim analysis, where overall survival of subject in the doublet arm, treated with weekly DP, was not superior to that of subjects in the D monotherapy arm.
Journal ArticleDOI
The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines.
Junichi Ishihara,Nagahiro Saijo,Yasutsuna Sasaki,Hidehiko Nakano,Akira Ozaki,Hidenobu Takahashi,Masanori Sakurai,Kazuhiko Nakagawa,Masaaki Iigo,Fumihiko Kanzawa,Akio Hoshi,Weon Seon Hong,James R. Jett,Terumi Takahashi +13 more
TL;DR: The mechanisms of the antitumor effect of rH-TNF were not due to inhibition of DNA and RNA synthesis of tumor cells, as determined by the colony assay, 3H-thymidine uptake assay, and 51Cr-release assay.
Journal ArticleDOI
Report from the second Japanese Urological Association–Japanese Society of Medical Oncology joint conference, 2007: ‘Diagnosis and treatment of urological malignant tumors: How can we promote subspecialists?’
Nagahiro Saijo,Tsuneharu Miki,Yoshinobu Kubota,Seiji Naito,Hideyuki Akaza,Shunji Takahashi,Hironobu Minami +6 more
TL;DR: This Meeting Report briefly discusses the themes of uro‐oncology education; collaboration of urologists and medical oncologists for treatment of advanced renal cell carcinoma; the role of Urologists in treatment of urological cancer; and collaboration between the JUA and the JSMO.